Page 50 - 82_01
P. 50
Coronary ischemia-reperfusion: role of nitric oxide and endothelin-1. A Review
(23):2881–3. Ferrera R. Low-pressure reperfusion alters
230. Botker HE, Kharbanda R, Schmidt MR, Bøttcher M, mitochondrial permeability transition. Am J Physiol
Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Heart Circ Physiol 2005;288 (6):H2750–5.
Hansen TM, Trautner S, Lassen JF, Christiansen EH,
Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, 241. Krause SM, Clayton FC, Williams DL Jr. Myocardial
Rehling M, Sørensen HT, Redington AN, Nielsen TT.
Remote ischaemic conditioning before hospital protection with the non-selective endothelin receptor
admission, as a complement to angioplasty, and effect
on myocardial salvage in patients with acute antagonist L-753, 037 following acute coronary artery
myocardial infarction: a randomised trial. Lancet. occlusion in the dog. J Cardiovasc Pharmacol2004; 43
2010; 375 (9716):727–34.
(2):214-21.
231. Le Page S, Bejan-Angoulvant T, Angoulvant D,
Prunier F. Remote ischemic conditioning and 242. Gonon AT, Bulhak A, Bröijersén A, Pernow J.
cardioprotection: a systematic review and meta- Cardioprotective effect of an endothelin receptor
analysis of randomized clinical trials. Basic Res antagonist during ischaemia/reperfusion in the
Cardiol 2015; 110 (2):11-27.
severely atherosclerotic mouse heart. Br J Pharmacol
232. Heusch G. Treatment of Myocardial 2005; 144 (6): 860–6.
Ischemia/Reperfusion Injury by Ischemic and
Pharmacological Postconditioning. Compr Physiol 243. Climent B, Fernández N, García-Villalón AL, Monge
2015; 5 (3):1123-45.
L, Sánchez A, Diéguez G. Effects of antagonists for
233. Rochitte CE, Rochitte, Lima JAC, Bluemke DA, MD,
Reede SBr, McVeigh ER, Furuta T, Becker LC, Melin endothelin ET (A) and ET (B) receptors on coronary
JA. Magnitude and time course of microvascular endothelial and myocardial function after ischemia-
obstruction and tissue injury after acute myocardial
infarction. Circulation 1998;98 (10):1006–14. reperfusion in anesthetized goats. Vascul Pharmacol.
2006; 44 (5):384-90
234. Ytrehus K, Liu Y, TsuchidaA, Miura T, Liu GS,
Yang XM, Herbert D, Cohen MV, Downey JM. Rat 244. Bibli S-I, Toli EV, Vilaeti AD, Varnavas VC,
and rabbit heart infarction: effects of anesthesia, Baltogiannis GG, Papalois A, Zenon S. Kyriakides
perfusate, risk zone, and method of infarct sizing. Am
J Physiol 1994;267 (6 pt 2):H2383–90. ZS, Kolettis TM. Endothelin-B Receptors and Left
Ventricular Dysfunction after Regional versus Global
235. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart Ischaemia-Reperfusion in Rat Hearts. Cardiol Res and
AD, Koch WJ. Darbepoetin alfa, a long-acting
erythropoietin analog, offers novel and delayed Practice Volume, 2012 Article ID 986813, https://dx.
cardioprotection for the ischemic heart. Am J Physiol
Heart Circ Physiol 2007;293 (1):H60–8. doi. org/10. 1155/2012/986813.
236. Doukas J, , Wrasidlo W, Noronha G, Dneprovskaia E, 245. Tamareille S, Terwelp M, Amirian J, Felli P, Zhang
Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh XQ, Barry WH, Smalling RW. Endothelin-1 release
D. Phosphoinositide 3-kinase gamma/delta inhibition
limits infarct size after myocardial during the early phase of reperfusion is a mediator of
ischemia/reperfusion injury. Proc Natl Acad Sci U S
A 2006;103 (52):19866–71. myocardial reperfusion injury. Cardiology 2013; 125
237. Spears JR, Prcevski P, Jiang A, Brereton GJ, Vander (4):242-9.
HR. Intracoronary aqueous oxygen perfusion,
performed 24 h after the onset of postinfarction 246. Rafnsson A, Shemyakin A, Pernow J. Selective
reperfusion, experimentally reduces infarct size and
improves left ventricular function. Int J Cardiol endothelin ETA and dual ET (A) /ET (B) receptor
2006;113 (3):371–5.
blockade improve endothelium-dependent
238. Roubille F, Franck-Miclo A, Covinhes A, Lafont C,
Cransac F, Combes S, Vincent A, Fontanaud P, vasodilatation in patients with type 2 diabetes and
Sportouch-Dukhan C, Redt-Clouet C, JNargeot J, Piot
C, Barrère-Lemaire S. Delayed postconditioning in the coronary artery disease. Life Sci 2014; 118 (2):435-9.
mouse heart in vivo. Circulation 2011;124 (12):1330–
6. 247. Adlbrecht C, Wurma R, Pezawasa T, Andreasb M,
Redwana B, Distelmaiera K, Kaiderc A, Langa IM.
239. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac
preconditioning for ischaemia: lost in translation. Dis Effects of endothelin A receptor blockade in patients
Model Mech 2010;3 (1–2):35–8.
with ST-elevation acute coronary syndrome — A
240. Bopassa JC, Michel P, Gateau-Roesch O, Ovize M,
rhythmologic substudy. Life Sci 2014; 118 (2):430–4.
248. Parkes DG, Vaughan J, Rivier J, Vale W, May CN.
Cardiac inotropic actions of urocortin in conscious
sheep. Am J Physiol 1997; 272:H2115-22.
249. Brar BK, Stephanou A, Okosi A, Lawrence KM,
Knight RA, Marber MS, Latchman DS. CRH-like
peptides protect cardiac myocytes from lethal
ischaemic injury. Mol Cell Endocrinol 1999; 158:55-
63.
250. Brar BK, Jonassen AK, Stephanou A, Santilli G,
Railson J, Knight RA, Yellon DM, Latchman DS.
Urocortin protects against ischemic and reperfusion
injury via a MAPK-dependent pathway. J Biol Chem
2000; 275: 8508-14.
251. Huang Y, Yao XQ, Lau CW, Chan YC, Tsang SY,
Chan FL. Urocortin and cardiovascular protection.
Acta Pharmacol Sin 2004; 25:257–65.
@Real Academia Nacional de Farmacia. Spain 49
